Health
Sequana Medical Announces Granting of Key Additional U.S. Patent for DSR
Ghent, Belgium, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Builds upon existing granted DSR patents in US, Europe, Japan and ChinaStrengthens DSR patent protection based upon extensive clinical and pre-clinical experienceData published in European Journal of Heart Failure supports DSR as breakthrough in treatment of cardiorenal syndrome and diuretic-resistant heart failureUS MOJAVE clinical study of DSR vs IV loop diuretics planned to enter randomized controlled phase following dedicated DSR financing Se
About this update from Sequana Medical N.v
[{"type":"image","alt":"Sequana Medical NV","displaySize":"","headline":null,"caption":"Sequana Medical NV","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":64,"url":"https://media.zenfs.com/en/globenewswire.com/eebd983759ebc3a966954513471e9960"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/I6pT.8uzi87Vh1qGIu6GAg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/eebd983759ebc3a966954513471e9960","width":300,"height":64}},"lazy":false},{"type":"text","content":"Ghent, Belgium, Dec. 18, 2025 (GLOBE NEWSWIRE) --","length":49,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Builds upon existing granted DSR patents in US, Europe, Japan and China","length":71,"tagName":"p"}]},{"val":[{"type":"text","content":"Strengthens DSR patent protection based upon extensive clinical and pre-clinical experience","length":91,"tagName":"p"}]},{"val":[{"type":"text","content":"Data published in European Journal of Heart Failure supports DSR as breakthrough in treatment of cardiorenal syndrome and diuretic-resistant heart failure","length":154,"tagName":"p"}]},{"val":[{"type":"text","content":"US MOJAVE clinical study of DSR vs IV loop diuretics planned to enter randomized controlled phase following dedicated DSR financing","length":131,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":447,"olType":false},{"type":"text","content":"Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announces the granting of a key additional US patent for the DSR (Direct Sodium Removal) programme. DSR is Sequana Medical’s drug development program for the treatment of cardiorenal syndrome and diuretic-resistant heart failure.","length":422,"tagName":"p"},{"type":"text","content":"U.S. patent number 12,496,384 B2 is entitled “Formulations and Methods for Direct sodium removal in patients having heart failure and/or severe renal dysfunction” and covers the DSR infusate and its method of operation. Specifically, it covers the use of a no or low sodium infusate that is administered to a patient’s peritoneal cavity to directly remove sodium, and thereby fluid from the body to alleviate fluid overload in heart failure patients with residual ...